Nouscom raises EUR 120 million in Series D co-led by M Ventures, Revelation Partners

By Public Technologies
  • Nouscom closed an oversubscribed EUR 120 million (USD 135 million) Series D financing co-led by M Ventures and Revelation Partners.
  • The clinical-stage biotech develops next-generation immunotherapies focused on cancer interception.
  • New investors included Angelini Industries, the European Investment Bank and Neva SGR; all existing investors participated.
  • Proceeds will advance lead cancer immunotherapy NOUS-209 through a global, registration-enabling trial for cancer interception in Lynch syndrome carriers.
  • NOUS-209 has received FDA Fast Track designation.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Merck Ventures BV published the original content used to generate this news brief on October 19, 2026, and is solely responsible for the information contained therein.

Capital Com is an execution-only service provider. The present material must be regarded as marketing communication and should not be interpreted as investment research or investment advice. Any opinion that may be provided on this page does not constitute a recommendation by Capital Com or its agents. We do not make any representations or warranty on the accuracy or completeness of the information that is provided on this page. If you rely on the information on this page, then you do so entirely at your own risk